$5.60 $0.40 (7.7%)

04:00 PM EDT on 08/16/19

Clovis Oncology (NASDAQ:CLVS)

CAPS Rating: 2 out of 5

Current Price $5.60 Mkt Cap $318.6M
Open $5.46 P/E Ratio 0.00
Prev. Close $5.20 Div. (Yield) $0.00 (0.0%)
Daily Range $5.45 - $5.85 Volume 5,473,927
52-Wk Range $4.98 - $32.05 Avg. Daily Vol. 37

Caps

How do you think NASDAQ:CLVS will perform against the market?

Add Stock to CAPS Watchlist

All Players

53 Outperform
16 Underperform
 

All-Star Players

18 Outperform
5 Underperform
 

Wall Street

6 Outperform
2 Underperform
 

Top NASDAQ:CLVS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.83)
Submitted February 16, 2016

Clovis isn't exactly flying under the radar ahead of the rociletinib Ad Comm on April 12. There's lots of commentary on the drug's prospects for approval, most of it negative. Of course, the shocking aspect of the whole situation was the blase way in… More

TerryHogan (99.97)
Submitted October 10, 2018

The financials on this one are fishier than a murder mystery dinner theater in Newfoundland. You can expect SG&A to go up in line with revenue a bit, but why does R&D increase with every revenue increase to wipe out all profits? I'm not saying… More

NASDAQ:CLVS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about CLVS.

Recs

0
Member Avatar Bigsef77 (68.66) Submitted: 10/2/2018 10:16:34 AM : Outperform Start Price: $12.96 NASDAQ:CLVS Score: -184.44

Clovis Oncology stock rises 10% premarket after 'breakthrough' designation from FDA

,MarketWatch•October 2, 2018
Clovis Oncology Inc. shares rose nearly 10% in Tuesday premarket trade after the company's cancer drug Rubraca got a "breakthrough therapy" designation from the Food and Drug Administration. The designation could expedite the development and review of Rubraca by the FDA for BRCA1/2-mutated metastatic castration-resistant prostate cancer. The company plans to present the phase 2 trial data that "served as the basis of our [breakthrough therapy designation] at the [European Society for Medical Oncology] conference later this month," Clovis Chief Executive Patrick Mahaffy said. Metastatic castration-resistant prostate cancer refers to a type of cancer that has spread beyond the prostate and continues to spread in spite of treatments intended to manage the disease. Called mCRPC, it is incurable and usually associated with poor prognosis, according to Clovis. Clovis is also testing Rubraca in a number of other types of cancer, including in combination with a Bristol-Myers Squibb immunotherapy; the drug has not been approved in the U.S. Clovis shares have dropped 35.5% over the last three months, compared with a 7.3% rise in the S&P 500 and a 9.6% rise in the Dow Jones Industrial Average .

Recs

0
Member Avatar Capitalism (84.19) Submitted: 2/26/2018 1:20:40 PM : Outperform Start Price: $55.12 NASDAQ:CLVS Score: -94.01

Richard Marzouka (SA) pick.

Recs

0
Member Avatar LifeScientist (28.08) Submitted: 2/17/2016 3:19:38 PM : Outperform Start Price: $19.78 NASDAQ:CLVS Score: -121.59

technical near term bottom and nice upside two day trend; no insider selling of late since the drop last Nov. ( however no buying reported for 12 mos. ) top fools ZZlangerhaus and Seth15701 like it and former had a reasonable analysis .... Note, due to announce on Feb 25, so have to decide whether to hold it through earnings, but street's got a good negative expect of cash burn. Credit Suisse has picked it up with an analysis and an outperform since the Nov price drop.

Leaderboard

Find the members with the highest scoring picks in CLVS.

Score Leader

anchak

anchak (99.92) Score: +387.02

The Score Leader is the player with the highest score across all their picks in CLVS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
kurzzz 73.26 6/25/2013 Underperform 5Y $65.00 -91.38% +82.20% +173.58 0 Comment
ExpressRocks 91.19 6/25/2013 Underperform 5Y $63.88 -91.23% +82.14% +173.38 0 Comment
bluebare 35.12 6/14/2013 Underperform 5Y $69.38 -91.93% +77.16% +169.09 0 Comment
kevian 94.89 6/3/2013 Underperform 1Y $71.74 -92.19% +75.93% +168.12 0 Comment
KidJones 34.61 12/3/2012 Underperform 5Y $15.59 -64.07% +103.89% +167.96 0 Comment
MFBurritoSquat 90.62 11/30/2012 Underperform 3M $15.81 -64.58% +103.29% +167.87 0 Comment
IBDContrarian 70.64 4/8/2013 Underperform 5Y $29.05 -80.72% +85.97% +166.69 1 Comment
goldminingXpert 28.78 5/13/2013 Underperform NS $37.75 -85.17% +76.34% +161.51 0 Comment
GuruExp 56.01 10/7/2014 Underperform 5Y $47.02 -88.09% +47.86% +135.95 0 Comment
navychop2 42.56 6/12/2014 Underperform 1Y $43.34 -87.08% +48.34% +135.42 2 Comments

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRBCCapMkts 84.33 2/22/2018 Outperform NS $58.88 -90.49% +6.51% -97.00 0 Comment
TrackCreditSuiss 88.18 9/21/2016 Outperform NS $37.28 -84.98% +34.78% -119.76 0 Comment
TrackGoldmanSach 75.43 4/13/2015 Outperform NS $84.50 +4.28% +1.37% +2.91 7/20/2015 @ $88.12 0 Comment
TrackStifel 91.45 6/5/2014 Outperform NS $39.65 -85.88% +49.29% -135.17 0 Comment
TrackJimCramer 86.43 10/1/2013 Outperform 3W $62.04 -90.97% +70.51% -161.49 0 Comment
TrackCitigroup 85.70 9/20/2013 Outperform NS $78.17 -48.43% +11.69% -60.13 6/3/2014 @ $40.31 0 Comment
trackmizuho < 20 6/25/2013 Outperform NS $65.00 -91.38% +82.20% -173.58 0 Comment
TrackJimCramer 86.43 6/14/2013 Underperform 3W $67.23 -7.72% +3.77% +11.49 10/1/2013 @ $62.04 0 Comment
TrackPiperJaff 84.76 6/6/2013 Outperform NS $74.00 -92.43% +79.13% -171.56 0 Comment
TrackUltraLong < 20 3/21/2013 Underperform NS $27.54 -79.67% +86.58% +166.25 1 Comment
TrackPoisedTo < 20 12/6/2012 Underperform 5Y $15.60 -64.10% +104.25% +168.35 0 Comment